Brain-targeted Drug Delivery by in Vivo Functionalized Liposome with Stable D-peptide Ligand.

Yang,Yuxiu Chu,Cheng Li,Lianfeng Fan,Huiping Lu,Changyou Zhan,Zui Zhang

DOI: https://doi.org/10.1016/j.jconrel.2024.07.014

IF: 11.467

2024-01-01

Journal of Controlled Release

Abstract:Brain-targeted drug delivery poses a great challenge due to the blood-brain barrier (BBB). In a previous study, we have developed a peptide-modified stealth liposome (SP-sLip) to enhance BBB penetration via the adsorption of apolipoproteins in plasma. SP is an 11-amino acid peptide derived from 25 to 35 of the Amyloid beta peptide (A beta(1-42)), which is a nature ligand of apolipoproteins. Although freshly prepared SP-sLip exhibited efficient brain targeting performance, it occured self-aggregation and instability in storage. In this study, we developed a D-peptide ligand according to the reverse sequence of SP with D-amino acids, known as (SP)-S-D, to improve the stability in storage. Notably, (SP)-S-D exhibited a reduced tendency for self-aggregation and improved stability in comparison to the SP peptide. Furthermore, compared to SP-sLip, (SP)-S-D-modified sLip ((SP)-S-D-sLip) demonstrated enhanced stability (>2 weeks), prolonged blood circulation (AUC increased 44.4%), reduced liver and spleen accumulation (reduced by 2.23 times and 1.86 times) with comparable brain-targeting efficiency. Similar to SP-sLip, (SP)-S-D-sLip selectively adsorbed apolipoprotein A1, E, and J in the blood to form functionalized protein corona, thus crossing BBB via apolipoprotein receptor-mediated transcytosis. These findings underscored the importance of ligand stability in the in vitro and in vivo performance of brain-targeted liposomes, therefore paving the way for the design and optimization of efficient and stable nanocarriers.